I'm a well-documented bear on ICPT, so we have no argument there. However, the LDL-raising property of Ocaliva does not necessarily extend to other FXR agonists, as some have alleged. Each compound has to be considered on its own merits.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.